LOADING...

Periodic Paralyses

Periodic Paralyses

No Results

No Results

processing….

The heterogeneous group of muscle diseases known as periodic paralyses (PP) is characterized by episodes of flaccid muscle weakness occurring at irregular intervals. Most of the conditions are hereditary and are more episodic than periodic. They can be divided conveniently into primary and secondary disorders.

General characteristics of primary PP include the following: (1) they are hereditary; (2) most are associated with alteration in serum potassium levels; (3) myotonia sometimes coexists; and (4) both myotonia and PP result from defective ion channels.

A clinically useful classification of primary periodic paralyses, shown in Table 1, includes hypokalemic, hyperkalemic, and paramyotonic forms.

Table 1. Primary Periodic Paralysis (modified from Jurkat-Rott and Lehmann-Horn [1] ) (Open Table in a new window)

Disease

Gene

Protein

Inheritance

Mutation

HyperPP

SCN4A

Nav1.4

Dominant

Gain

NormoPP

 

 

 

Gain (ω-pore)

Paramyotoniacongenita

Gain

HypoPP Type II

Gain (ω-pore)

HypoPP Type I

CACNA1S

Cav1.1

Dominant

Gain (ω-pore)

ThyrotoxicPP

KCNJ18

Kir2.18

Dominant

Loss

Andersen-Tawil syndrome

KCNJ2

Kir2.1

Dominant

Loss

 

The physiologic basis of flaccid weakness is inexcitability of the muscle membrane (ie, sarcolemma). Alteration of serum potassium level is not the principal defect in primary PP; the altered potassium metabolism is a result of the PP. In primary and thyrotoxic PP, flaccid paralysis occurs with relatively small changes in the serum potassium level, whereas in secondary PP, serum potassium levels are markedly abnormal.

No single mechanism is responsible for this group of disorders. Thus, they are heterogeneous but share some common traits. The weakness usually is generalized but may be localized. Cranial musculature and respiratory muscles usually are spared. Stretch reflexes are either absent or diminished during the attacks. The muscle fibers are electrically inexcitable during the attacks. Muscle strength is normal between attacks but, after a few years, some degree of fixed weakness develops in certain types of PP (especially primary PP). All forms of primary PP (except Becker myotonia congenita [MC]) are either autosomal dominant inherited or sporadic (most likely arising from point mutations).

Voltage-sensitive ion channels closely regulate generation of action potentials (brief and reversible alterations of the voltage of cellular membranes). These are selectively and variably permeable ion channels. Energy-dependent ion transporters maintain concentration gradients. During the generation of action potentials, sodium ions move across the membrane through voltage-gated ion channels. The resting muscle fiber membrane is polarized primarily by the movement of chloride through chloride channels and is repolarized by movement of potassium. Sodium, chloride, and calcium channelopathies, as a group, are associated with myotonia and PP. The functional subunits of sodium, calcium, and potassium channels are homologous. Sodium channelopathies are better understood than calcium or chloride channelopathies. All forms of familial PP show the final mechanistic pathway involving aberrant depolarization, inactivating sodium channels, and muscle fiber inexcitability.

Discussion in this article primarily addresses the sodium, calcium, and potassium channelopathies as well as secondary forms of PP. Chloride channelopathies are not associated with episodic weakness and are discussed in more detail in the articles on myotonic disorders.

With HyperPP fast channel inactivation, mutations are usually situated in the inner parts of transmembrane segments or in the intracellular loops affecting the docking sites for the fast inactivating particle, thus impairing fast channel inactivation leading to persistent Na+ current.

With HypoPP hyperpolarization-activated cation leak counteracting K+ -rectifying current, mutations cause outermost arginine or lysine substitution.

With NormoPP depolarization-activated cation leak, mutations are in deeper locations of voltage sensor of domain II at codon R675. [1, 2]

Ion channel dysfunction is usually well compensated with normal excitation, and additional triggers are often necessary to produce muscle inexcitability owing to sustained membrane depolarization.

Glucose and potassium intake has the opposite effects in these disorders. In HyperPP, potassium intake triggers the attack, whereas glucose ameliorates it. In contrast, glucose provokes hypokalemic attacks and potassium is the treatment for the attack. [2]

Note the image below.

The sodium channel has an alpha subunit and a beta subunit. The alpha subunit of the sodium channel is a 260-kd glycoprotein comprising about 1800-2000 amino acids. This channel is highly conserved evolutionarily from Drosophila to human. It has 4 homologous domains (I-IV) that fold to form a central pore, each with 225-325 amino acids. Each domain consists of 6 hydrophobic segments (S1-S6) traversing the cell membrane. The main functions of the channel include voltage-sensitive gating, inactivation, and ion selectivity. The extracellular loop between S5 and S6 dips into the plasma membrane and participates in the formation of the pore. The S4 segment contains positively charged amino acids at every third position and functions as a voltage sensor. Conformation changes may occur during depolarization, resulting in activation and inactivation of the channel. The cellular loop between domain III-S6 and domain IV-S1 acts as an inactivating gate.

The sodium channel has 2 gates (activation and inactivation) and can exist in 3 states. At rest with the membrane polarized, the activation gate is closed and the inactivation gate is opened. With depolarization, the activation gate opens, allowing sodium ions to pass through the ion channel and also exposing a docking site for the inactivation gate. With continued depolarization, the inactivation gate closes, blocking the entry of sodium into the cell and causing the channel to enter the fast-inactivation state. This inactivation of the channel allows the membrane to become repolarized, resulting in a return to the resting state with the activation gate closed and the inactivation gate opened. Two inactivation processes occur in mammalian skeletal muscle: Fast inactivation involves terminating the action potential and acts on a millisecond time scale. Slow inactivation takes seconds to minutes and can regulate the population of excitable sodium channels.

Sodium channel mutations that disrupt fast and slow inactivation are usually associated with a phenotype of HyperPP and myotonia, where as mutations that enhance slow or fast inactivation producing loss of sodium channel function cause HypoPP.

Mutations of the sodium channel gene (SCN4A) have several general features. Most of the mutations are in the “inactivating” linker between repeats III and IV, in the “voltage-sensing” segment S4 of repeat IV or at the inner membrane where they could impair the docking site for the inactivation gate. The clinical phenotype differs by specific amino acid substitution and, while some overlap may occur between hyperkalemic PP, paramyotonia congenita (PC), and potassium-aggravated myotonias (PAM), the 3 phenotypes are generally distinct (as described below). Nearly all mutant channels have impaired fast-inactivation of sodium current. Most patients are sensitive to systemic potassium or to cold temperature.

Two populations of channels exist, mutant and wild-type; the impaired fast-inactivation results in prolonged depolarization of the mutant muscle fiber membranes and can explain the 2 cardinal symptoms of these disorders, myotonia and weakness. In hyperkalemic PP, a gain of function occurs in mutant channel gating, resulting in an increased sodium current excessively depolarizing the affected muscle. Mild depolarization (5-10 mV) of the myofiber membrane, which may be caused by increased extracellular potassium concentrations, results in the mutant channels being maintained in the noninactivated mode. The persistent inward sodium current causes repetitive firing of the wild-type sodium channels, which is perceived as stiffness (ie, myotonia).

If a more severe depolarization (20-30 mV) is present, both normal and abnormal channels are fixed in a state of inactivation, causing weakness or paralysis. Thus, subtle differences in severity of membrane depolarization may make the difference between myotonia and paralysis. Temperature sensitivity is a hallmark of PC. Cold exacerbates myotonia and induces weakness. A number of mutations are associated with this condition, 3 of them at the same site (1448) in the S4 segment. These mutations replace arginine with other amino acids and neutralize this highly conserved S4 positive charge. Mutations of these residues are the most common cause of PC. Some of the possible mechanisms responsible for temperature sensitivity include the following:

Temperature may differentially affect the conformational change in the mutant channel.

Lower temperatures may stabilize the mutant channels in an abnormal state.

Mutations may alter the sensitivity of the channel to other cellular processes, such as phosphorylation or second messengers.

Most cases of hyperkalemic PP are due to 2 mutations in SCN4A, T704M, and M1592V. Mutations in the sodium channel, especially at residues 1448 and 1313, are responsible for paramyotonia congenita. A small proportion of hypokalemic periodic paralysis cases are associated with mutations at codons 669 and 672 (HypoPP2). In HypoPP2, sodium channel mutations enhance inactivation to produce a net loss of function defect.

Normokalemic PP resembles both HyperPP (potassium sensitivity) and HypoPP (duration of attacks) and is caused by SCN4A mutations at a deeper location of voltage sensor DII at codon 675. R675 mutations differ from HypoPP in that these mutations result in depolarization-activated gating pore generating ω-current with reversed voltage dependence as this site is exposed to extracellular sites at stronger depolarization. [3]

The calcium channel gene (CACNL1A3) is a complex of 5 subunits (alpha-1, alpha-2, beta, gamma, and delta). The skeletal muscle dihydropyridine (DHP) receptor is located primarily in the transverse tubular membrane. The alpha-1 subunit has binding sites for DHP drugs and conducts the slow L-type calcium current. It also participates in excitation-contraction (EC) coupling and acts as a voltage sensor through its linkage with the ryanodine receptor of sarcoplasmic reticulum (ie, calcium release channel). Any changes in the membrane potential are linked to intracellular calcium release, enabling EC coupling. Point mutations in DHP receptor/calcium channel alpha-1 subunit cause hypokalemic PP (HypoPP1). Two mutations of CACNA1S gene, R528H and R1239H, are responsible for most cases of hypokalemic PP.

The physiological basis of disease is still not understood, but is more likely due to a failure of excitation rather than a failure of EC coupling. However, hypokalemia-induced depolarization may reduce calcium release, affecting the voltage control of the channel directly or indirectly through inactivation of the sodium channel. Insulin and adrenaline may act in a similar manner. Mutations of the calcium channel gene have some similarities to SCN4A mutations. Mutations modify channel inactivation but not voltage-dependent activation. Recordings from myotube cultures from affected patients revealed a 30% reduction in the DHP-sensitive L-type calcium current. Channels are inactivated at low membrane potentials.

Calcium channel mutations cause a loss of function manifested as a reduced current density and slower inactivation. How this inactivation is related to hypokalemia-induced attacks is not understood. At least in R528H mutation, a possible secondary channelopathy occurs, tied to a reduction in the ATP-sensitive potassium current from altered calcium homeostasis. The lower currents associated with CACNL1A3 mutations could slightly alter intracellular calcium homeostasis, which could affect the properties and expression of K+ channels, particularly KATP (ATP-sensitive potassium channel) belonging to inward rectifier class of channels. Insulin also acts in HypoPP by reducing this inward rectifier K+ current.

Voltage sensor charge loss accounts for most cases of HypoPP. Sodium and calcium channels have homologous pore-forming alfa subunits. Point mutations in CACNL1A3 and SCN4A affect argentine residues in the S4 voltage sensors of these channels. Arginine mutations in S4 segments are responsible for 90% of HypoPP cases. [4]

Voltage sensor charge loss accounts for most cases of HypoPP. Sodium and calcium channels have homologous pore-forming α subunits. Almost all of the mutations in Cav1.1 (HypoPP-1) and Nav1.4 (HypoPP-2) neutralize a positively charged amino acid in one of the outermost arginines or lysines of voltage sensors. The Nav1.4 mutations are most commonly situated in the voltage sensors of I, II, and III repeats, causing a cation leak.

Substitution of outermost arginine with a smaller amino acid such as glycine opens a conductive pathway at hyperpolarized potential, resulting in an inward cation current (cation leak or ω current to distinguish from (ω-) through ion–conducting pore, is a hyperpolarization-activated current of monovalent cations through S4 gating pore counteracting rectifying K+ currents) depolarizing or destabilizing the resting potential.

S4 segment moves outward during depolarization closing the conductive pathway. Muscle fibers with severe voltage sensor mutations are depolarized not only during hypokalemia but also at potassium levels in the normal range, explaining interictal and permanent weakness. Severe myopathy with fatty replacement of muscle tissue is commonly found in patients with Cav1.1 R1239H (DIV mutations). [1]

Glucocorticosteroids cause HypoPP by stimulating Na+ K+ ATPase mediated by insulin and amylin. [5]

Inward rectification is an important property of Kir channels. Rectification involves voltage-dependent conduction-pore blockage of pore with polyamines and Mg++ during depolarization, and this blockage is removed during potential gradient during hyperpolarization. Potassium channel mutations are seen in Andersen-Tawil syndrome and thyrotoxic PP.

The triad of dysmorphic features, periodic paralysis, and cardiac arrhythmias characterizes Andersen-Tawil syndrome. This syndrome is associated with mutations in the KCNJ2 gene. [6] The KCNJ2 gene encodes the inward-rectifying potassium channel Kir2.1. Potassium channel mutations in KCNE3 are reported to cause hypokalemic PP, but this has not been substantiated.

Mutations in Kir2.6 cause susceptibility to thyrotoxic PP. Episodic weakness seen in thyrotoxic PP is similar to that seen in HypoPP and Andersen-Tawil syndrome. This disorder is most prevalent in Asians and Latin American men. Thyrotoxic PP is a genetic disorder unmasked by thyrotoxicosis. Kir2.6 is primarily expressed in skeletal muscle. Triiodothyronine enhances KCNJ18 transcription, which may drive enhanced expression of Kir2.6. PKC is activated during thyrotoxicosis because of increased PIP2 turnover and Kir channels directly interact with PIP2 during normal gating. In Andersen-Tawil syndrome, there is decreased PIP2 affinity. In thyrotoxic PP, none of the mutations alters Kir2.6 rectification. [7]

The frequencies of hyperkalemic periodic paralysis, paramyotonia congenita (PC), and potassium-aggravated myotonias (PAM) are not known. Hypokalemic periodic paralysis has a prevalence of 1 case per 100,000 population.

Thyrotoxic PP is most common in males (85%) of Asian descent with a frequency of approximately 2%.

Jurkat-Rott K, Lehmann-Horn F. State of the art in hereditary muscle channelopathies. Acta Myol. 2010 Oct. 29(2):343-50. [Medline].

Francis DG, Rybalchenko V, Struyk A, Cannon SC. Leaky sodium channels from voltage sensor mutations in periodic paralysis, but not paramyotonia. Neurology. 2011 May 10. 76(19):1635-41. [Medline].

Sokolov S, Scheuer T, Catterall WA. Depolarization-activated gating pore current conducted by mutant sodium channels in potassium-sensitive normokalemicperiodic paralysis. ProcNatlAcadSci USA. 2008. 105:19980-5.

Matthews E, Labrum R, Sweeney MG, Sud R, Haworth A, Chinnery PF, et al. Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology. 2009 May 5. 72(18):1544-7. [Medline]. [Full Text].

Arzel-Hezode M, McGoey S, Sternberg D, Vicart S, Eymard B, Fontaine B. Glucocorticoids may trigger attacks in several types of periodic paralysis. Neuromuscul Disord. 2009 Mar. 19(3):217-9. [Medline].

Donaldson MR, Yoon G, Fu YH, Ptacek LJ. Andersen-Tawil syndrome: a model of clinical variability, pleiotropy, and genetic heterogeneity. Ann Med. 2004. 36 Suppl 1:92-7. [Medline].

Ryan DP, da Silva MR, Soong TW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell. 2010 Jan 8. 140(1):88-98. [Medline]. [Full Text].

Statland JM, Fontaine B, Hanna MG, Johnson NE, Kissel JT, Sansone VA, et al. Review of the Diagnosis and Treatment of Periodic Paralysis. Muscle Nerve. 2018 Apr. 57 (4):522-530. [Medline].

Chalissery AJ, Munteanu T, Langan Y, Brett F, Redmond J. Diverse phenotype of hypokalaemic periodic paralysis within a family. Pract Neurol. 2018 Feb. 18 (1):60-65. [Medline].

Siddiqui FA, Sheikh A. Muscle paralysis in thyrotoxicosis. BMJ Case Rep. 2015 May 29. 2015:[Medline].

Chaudhry MA, Wayangankar S. Thyrotoxic Periodic Paralysis: A Concise Review of the Literature. Curr Rheumatol Rev. 2016. 12 (3):190-194. [Medline].

Dias Da Silva MR, Cerutti JM, Arnaldi LA, Maciel RM. A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J Clin Endocrinol Metab. 2002 Nov. 87(11):4881-4. [Medline].

Assadi F. Diagnosis of hypokalemia: a problem-solving approach to clinical cases. Iran J Kidney Dis. 2008 Jul. 2(3):115-22. [Medline].

Streib EW. AAEE minimonograph #27: Differential diagnosis of myotonic syndromes. Muscle Nerve. 1987 Sep. 10(7):603-15. [Medline].

Fournier E, Arzel M, Sternberg D, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol. 2004 Nov. 56(5):650-61. [Medline].

Keveyis (dichlorphenamide) [package insert]. Hawthorne, NY: Taro Pharmaceuticals. August 2015. Available at [Full Text].

Levitt JO. Practical aspects in the management of hypokalemic periodic paralysis. J Transl Med. 2008 Apr 21. 6:18. [Medline]. [Full Text].

Matthews E, Portaro S, Ke Q, et al. Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype. Neurology. 2011 Nov 29. 77(22):1960-4. [Medline]. [Full Text].

Junker J, Haverkamp W, Schulze-Bahr E, Eckardt L, Paulus W, Kiefer R. Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome. Neurology. 2002 Aug 13. 59(3):466. [Medline].

Pellizzón OA, Kalaizich L, Ptácek LJ, Tristani-Firouzi M, Gonzalez MD. Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome. J Cardiovasc Electrophysiol. 2008 Jan. 19(1):95-7. [Medline].

Elbaz A, Vale-Santos J, Jurkat-Rott K. Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families. Am J Hum Genet. 1995 Feb. 56(2):374-80. [Medline].

Engel AG, Lambert EH, Rosevear JW, Tauxe WN. Clinical and electromyographic studies in a patient with primary hypokalemic periodic paralysis. Am J Med. 1965 Apr. 38:626-40. [Medline].

Griggs RC. Evaluation and Treatment of Myopathies. Philadelphia: FA Davis; 1995: 318-354.

Hoffman EP, Lehmann-Horn F, Rudel R. Overexcited or inactive: ion channels in muscle disease. Cell. 1995 Mar 10. 80(5):681-6. [Medline].

Junker J, Haverkamp W, Schulze-Bahr E, et al. Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome. Neurology. 2002 Aug 13. 59(3):466. [Medline].

Koch MC, Steinmeyer K, Lorenz C. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science. 1992 Aug 7. 257(5071):797-800. [Medline].

Lin SH, Lin YF, Chen DT, et al. Laboratory tests to determine the cause of hypokalemia and paralysis. Arch Intern Med. 2004 Jul 26. 164(14):1561-6. [Medline].

McManis PG, Lambert EH, Daube JR. The exercise test in periodic paralysis. Muscle Nerve. 1986 Oct. 9(8):704-10. [Medline].

Meola G, Sansone V. Treatment in myotonia and periodic paralysis. Rev Neurol (Paris). 2004 May. 160(5 Pt 2):S55-69. [Medline].

Miller TM, Dias da Silva MR, Miller HA, et al. Correlating phenotype and genotype in the periodic paralyses. Neurology. 2004 Nov 9. 63(9):1647-55. [Medline].

Platt D, Griggs R. Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias. Curr Opin Neurol. 2009 Oct. 22(5):524-31. [Medline]. [Full Text].

Ptacek L. The familial periodic paralyses and nondystrophic myotonias. Am J Med. 1998 Jul. 105(1):58-70. [Medline].

Ptacek LJ, Johnson KJ, Griggs RC. Genetics and physiology of the myotonic muscle disorders. N Engl J Med. 1993 Feb 18. 328(7):482-9. [Medline].

Ruff RL. Slow inactivation: slow but not dull. Neurology. 2008 Mar 4. 70(10):746-7. [Medline].

Tricarico D, Barbieri M, Mele A, et al. Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channelof K+-deficient rats. FASEB J. 2004 Apr. 18(6):760-1. [Medline].

Venance SL, Cannon SC, Fialho D, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain. 2006 Jan. 129(Pt 1):8-17. [Medline].

Zhang J, George AL, Griggs RC. Mutations in the human skeletal muscle chloride channel gene (CLCN1) associated with dominant and recessive myotonia congenita. Neurology. 1996 Oct. 47(4):993-8. [Medline].

Disease

Gene

Protein

Inheritance

Mutation

HyperPP

SCN4A

Nav1.4

Dominant

Gain

NormoPP

 

 

 

Gain (ω-pore)

Paramyotoniacongenita

Gain

HypoPP Type II

Gain (ω-pore)

HypoPP Type I

CACNA1S

Cav1.1

Dominant

Gain (ω-pore)

ThyrotoxicPP

KCNJ18

Kir2.18

Dominant

Loss

Andersen-Tawil syndrome

KCNJ2

Kir2.1

Dominant

Loss

Syndrome

Age of Onset

Duration of Attack

Precipitating

Factors

Severity of Attacks

Associated

Features

Hyper-kalemic periodic paralyses

First decade of life

Few minutes to less than 2 h (mostly less than 1 h)

Low carbohydrate intake (fasting)

Cold

Rest following exercise

Alcohol

Infection

Emotional stress

Trauma

Menstrual period

Rarely severe

Perioral and limb paresthesias

Myotonia frequent

Occasional pseudo-hypertrophy of muscles

Hypo-kalemic periodic paralyses

Variable -Childhood to third decade

Majority of cases before 16 years

Few hours to almost a week

Typically no longer than 72 h

Early morning attacks after previous day physical activity

High-carbohydrate meal, Chinese food, alcohol

Cold, change in barometric pressure or humidity

Fever, upper respiratory tract infections

Lack of sleep,

fatigue

Menstrual cycle

Severe

Complete paralysis

Occasional myotonic lid lag

Myotonia between attacks rare

Unilateral, partial, monomelic

Fixed muscle weakness late in disease

Potassium- associated myotonia

First decade

No weakness

Cold

Rest after exercise

Attacks of stiffness can be mild to severe

Muscle hypertrophy

Para-myotonia congenita

First decade

2-24 h

Cold

Rarely severe

Pseudo-hypertrophy of muscles

Paradoxical myotonia

Fixed weakness rare

Thyrotoxic periodic paralyses

Third and fourth decades

Few hours to 7 d

Same as hypokalemic PP

Hyper-insulinemia

Same as hypokalemic PP

Fixed muscle weakness may develop

Hypokalemia during attacks

Hypokalemic

Hyperkalemic

Urinary potassium-wasting syndromes

Hyperaldosteronism

Conn syndrome

Bartter syndrome

Licorice intoxication

 

Alcohol

Addison disease

Chronic renal failure

Hyporeninemic

Hypoaldosteronism

Drugs – Amphotericin B, barium

Ileostomy with tight stoma

Renal tubular acidosis

Potassium load

GI potassium-wasting syndromes

Laxative abuse

Severe diarrhea

Potassium-sparing diuretics

Disorder

Pattern and

Distribution of

Weakness

Transient ischemic attacks

Follow CNS distribution (ie, hemiparetic)

May have sensory symptoms and signs

Sleep attacks

Occur at onset or termination of sleep

Last only minutes

Myelopathy

Traumatic

Transverse myelitis

Ischemic

Sensory symptoms

Presence of a sensory level

Sphincter involvement

Myasthenia gravis

Lambert-Eaton myasthenic syndrome

Subacute in onset

Associated autonomic symptoms in LEMS

Hyporeflexia in LEMS

Abnormal repetitive nerve stimulation

Presence of distinct antibodies

Peripheral neuropathy of acute onset

Acute inflammatory

demyelinating poly-radiculoneuropathy

Porphyria

Pattern of weakness

Absent stretch reflexes

Toxins

Ciguatera

Tetrodotoxin

Clinical presentation

Urine K/C Ratio

Acid Base Status

Other Associated Features

Medical

Conditions

< 1.5

Metabolic acidosis

 

Lower GI loss – Laxative abuse, diarrhea

< 1.5

Metabolic alkalosis

Normal BP

Surreptitious vomiting

>1.5

Metabolic acidosis

 

DKA, type 1 or type 2 distal RTA

>1.5

Metabolic alkalosis

Normal BP

Diuretic use, Bartter syndrome, Gitelman syndrome

≥1.5

Metabolic alkalosis

Hypertension

Primary aldosteronism, Cushing syndrome, renal artery stenosis, congenital adrenal hyperplasia, apparent mineralocorticoid excess, Liddle syndrome

 

Hypokalemic PP

Hyperkalemic PP

Serum potassium

Mildly depressed; may reach 1-5 mEq/L

Increases from baseline but may not increase beyond normal range

Serum CPK

Moderately elevated during attacks

Mildly elevated during attacks

ECG

Bradycardia

Flat T waves, U waves, ST-segment depression

Tall T waves

 

Para-

myotonia

Congenita

Hyper-

kalemic

Periodic Paralysis

Hypo-

kalemic

Periodic Paralysis

Electrophysiological

pattern

I

IV

V

Channel mutations

Sodium T1313M, R1448C

Sodium T704M

Calcium R528H

Short Exercise Test:

 

 

 

Post exercise myotonic potentials

Yes

No

No

CMAP amplitude

change after First trial

Increase or

decrease

Increase

No

CMAP amplitude

change after second

and third trial

Gradual

increase

Gradual

increase

No

Long Exercise Test:

 

 

 

Immediate change of

CMAP amplitude

Decrease

Increase

No

Late change of CMAP amplitude

Decrease

Decrease

Decrease

Modified from Fournier et al, 2004. [15]

Naganand Sripathi, MD Director, Neuromuscular Clinic, Department of Neurology, Henry Ford Hospital

Naganand Sripathi, MD is a member of the following medical societies: American Academy of Neurology, American Medical Association, Michigan State Medical Society, New York Academy of Sciences

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Glenn Lopate, MD Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University in St Louis School of Medicine; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, Phi Beta Kappa

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Alnylam Pharmaceuticals<br/>Received income in an amount equal to or greater than $250 from: Alnylam Pharmaceuticals; GLG.

Nicholas Lorenzo, MD, MHA, CPE Co-Founder and Former Chief Publishing Officer, eMedicine and eMedicine Health, Founding Editor-in-Chief, eMedicine Neurology; Founder and Former Chairman and CEO, Pearlsreview; Founder and CEO/CMO, PHLT Consultants; Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, MHA, CPE is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Association for Physician Leadership

Disclosure: Nothing to disclose.

Paul E Barkhaus, MD, FAAN, FAANEM Professor of Neurology and Physical Medicine and Rehabilitation, Chief, Neuromuscular and Autonomic Disorders Program, Director, ALS Program, Department of Neurology, Medical College of Wisconsin

Paul E Barkhaus, MD, FAAN, FAANEM is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Clinical Neurophysiology Society, American Neurological Association

Disclosure: Nothing to disclose.

Periodic Paralyses

Research & References of Periodic Paralyses|A&C Accounting And Tax Services
Source

12 Replies to “Periodic Paralyses”

  1. Pingback: viagra 100mg
  2. Pingback: viagra generic
  3. Pingback: cialis generic
  4. Pingback: viagra
  5. Pingback: sildenafil citrate
  6. Pingback: buy viagra
  7. Pingback: generic cialis
  8. Pingback: generic viagra
  9. Pingback: viagra online
  10. Pingback: viagra price

Leave a Reply